Currently, there are no FDA-approved treatments for all stages of NASH, which will be the most common indication for liver transplantation by 2020 in the U. S., according to a press release.
目前，还没有FDA批准的用于治疗各个阶段NASH的药物，而到2020年NASH将会成为美国需要进行肝移植最常见的疾病。
Currently, there are no FDA-approved treatments for all stages of NASH, which will be the most common indication for liver transplantation by 2020 in the U. S., according to a press release.
目前，还没有FDA批准的用于治疗各个阶段NASH的药物，而到2020年NASH将会成为美国需要进行肝移植最常见的疾病。
应用推荐